Physician profile
William Mcpeters
NPI 1396849766
$1,481.45
in general payments reported to CMS, 2019-2025
22 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.78 · 2020: $164 · 2021: $201 · 2022: $221 · 2023: $314 · 2024: $239 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $378.57 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $325.18 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $103.96 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $68.40 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $54.69 | 2022-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $53.49 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $53.06 | 2023-2024 | Gvoke Hypopen |
| Viiv Healthcare Company | $49.30 | 2023-2024 | Dovato, Apretude |
| Pfizer INC. | $49.17 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $45.68 | 2020-2024 | Breztri |
| Astellas Pharma US INC | $45.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.46 | 2022-2023 | |
| Sanofi Pasteur INC. | $37.40 | 2023 | |
| Sunovion Pharmaceuticals INC. | $36.93 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $24.91 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.22 | 2020 | |
| Vanda Pharmaceuticals INC. | $20.99 | 2019 | |
| Abbott Laboratories | $19.34 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $15.85 | 2023 | Verquvo, Steglatro, Belsomra |
| Eisai INC. | $14.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.37 | 2025 | |
| Phathom Pharmaceuticals, INC. | $7.58 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcpeters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.